Concurrent somatic KRAS mutation and germline 10q22.3-q23.2 deletion in a patient with juvenile myelomonocytic leukemia, developmental delay, and multiple malformations: a case report

Ruen Yao 1,2, Tingting Yu 1,2*, Yufei Xu 1,2, Guoqiang Li 1,2, Lei Yin 3,4, Yunfang Zhou 4, Jian Wang 1,2 and Zhilong Yan 5*

Abstract

Background: The proto-oncogene KRAS performs an essential function in normal tissue signaling, and the mutation of KRAS gene is a key step in the development of many cancers. Somatic KRAS mutations are often detected in patients with solid and non-solid tumors, whereas germline KRAS mutations are implicated in patients with the Noonan syndrome, cardio-facio-cutaneous (CFC) syndrome and Costello syndrome. The deletion of chromosome 10q22.3-q23.2 is a rare cytogenetic abnormality, which often leads to distinct facial appearance and delays in speech and global development.

Case presentation: Herein, we report the case of a 4-year-old boy diagnosed with juvenile myelomonocytic leukemia. The boy also had syndromic features, such as speech and motor developmental delay, multiple congenital malformations, including distinct facial features, club feet, and cryptorchidism. Using whole-exome sequencing, we identified a pathogenic mutation in KRAS [c.34G > A, p.Gly12Ser] isolated from peripheral blood DNA. Sanger sequencing confirmed the wild-type sequence in the parents and patient's salivary cell DNA indicating its somatic state. A 7311-kb deletion in 10q22.3-q23.2 was also revealed by chromosomal microarray analysis, which was later proved as a germline de novo variant.

Conclusion: Juvenile myelomonocytic leukemia in the patient was attributed to a somatic KRAS mutation, whereas the syndromic features of the patient were considered a consequence of germline chromosome 10q22.3-q23.2 deletion. Genetic testing for patients with complicated phenotypes can be valuable in detecting multiple pathogenic variants.

Keywords: KRAS, 10q deletion, Juvenile myelomonocytic leukemia, Developmental delay, Whole-exome sequencing

Background

KRAS, as a member of the RAS gene family, encodes the cellular homolog of a transforming gene from the Kirsten rat sarcoma virus, which plays a vital role in normal tissue signaling, including proliferation, differentiation, and senescence. Germline or somatic mutations of KRAS are implicated in several human diseases like the Noonan syndrome [1], cardio-facio-cutaneous (CFC) syndrome [2], and Costello syndrome [3], as well as in different types of solid and non-solid tumor [4, 5]. KRAS is considered one of the most activated oncogenes, with 17% to 25 of all human tumors harboring an activating KRAS mutation [6].

Deletions of chromosome 10q22.3-q23.2, including that of the BMPRIA gene, have been associated with dysmorphic facies, developmental delay, and multiple congenital anomalies [7]. Recurrent deletions in this region derived from nonallelic homologous recombination.

* Correspondence: yutingting@scmc.com.cn; dryanzhilong@163.com
1Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, People’s Republic of China
2Department of Pediatric Surgery, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
(NAHR) between two well-defined low-copy repeats (LCRs) [8]. Larger deletions encompassing the PTEN gene could lead to the development of a more severe phenotype with infantile/juvenile polyposis and macrocephaly [9].

Herein, we report concurrent somatic KRAS mutation and germline chromosome 10q22.3-q23.2 deletion in a patient with juvenile myelomonocytic leukemia, developmental delay, and multiple congenital malformations, including distinct facial features, club feet, and cryptorchidism.

**Case presentation**

A 4-year-old boy was referred to our hospital because of respiratory tract infection, splenomegaly, and thrombocytopenia. The mother was 26-year-old, and the father was 31-year-old; both were of Chinese origin, non-consanguineous and healthy. The patient had two healthy sisters. The prenatal history was unremarkable, and the patient was born via a normal delivery at term. His birth weight was 3000 g, height 50 cm, and occipito-frontal circumference 36 cm. Family history did not show any congenital malformations.

On admission, the patient showed distinct facial features, including low nasal bridge, prominent epicanthic fold, hypertelorism, and low-set ears (Fig. 1). Enlargement of the liver and spleen was also observed. Furthermore, he had congenital bilateral club feet and cryptorchidism, as well as delayed speech and motor development. A routine blood test indicated an abnormal increase of white blood cell count and hypochromic anemia. As a common symptom of JMML patients, anemia occurs when bone marrow is overcrowded by leukemia cells. Bone marrow aspiration smear revealed trilineage myelodysplasia and decreased platelet production from megakaryocyte. The diagnosis of juvenile myelomonocytic leukemia (JMML) was based on the fulfilling these criteria: (1) absence of Philadelphia chromosome or BCR/ABL fusion gene; (2) peripheral blood mononuclear cell count: 9.2×10⁹/L, peripheral blood lymphocyte count: 8.2×10⁹/L; (3) less than 20% blasts (including promonocytes) in the blood and bone marrow; (4) immature granulocytes and nucleated red cells in the peripheral blood; (5) white blood cell count > 10×10⁹/L (peripheral white blood cell count: 23.9×10⁹/L); (6) splenomegaly. The patient died before chemotherapy could be started and bone marrow transplantation performed due to severe infection. The CARE guidelines were followed in reporting this case.

**Whole-exome sequencing and chromosomal microarray analysis**

Patient’s peripheral blood DNA was subjected to whole-exome sequencing to screen for causal variants. Briefly, 3 μg DNA was sheared to create fragments of 150–200 bp in size. An adaptor-ligated library was prepared using the paired-end sequencing library prep kit (Agilent Technologies, Santa Clara, CA, USA) and both the coding exons and flanking intronic regions were enriched with SureSelect XT Human All Exon V5 (Agilent Technologies). Then, clusters were generated by isothermal bridge amplification with an Illumina eBot station, and sequencing was performed with an Illumina HiSeq 2500 System (Illumina, San Diego, CA, USA).
A somatic mutation in the twelfth codon of KRAS (G12C) [16], and bladder cancer (G12R) [17]. Germline mutations contribute to a range of diseases or syndromes, grouped as RASopathy, which exhibit numerous overlapping phenotypic features involving multiple systems and organs due to common underlying Ras/MAPK pathway dysregulation. RASopathy-related syndromes, such as the Noonan syndrome, CFC syndrome, and Costello syndrome, can be detected in patients with germline mutations in the KRAS gene rather than with somatic mutations. Thus, in our study, the somatic G12S mutation detected in patient’s peripheral blood DNA, which was later confirmed to be absent from his parents and buccal swab, was considered a critical factor for the development of his JMML phenotype independent of his other symptoms.

Sporadic cases have been reported to show improvement over 2–4 year period without chemotherapy or hematopoietic cell transplantation (HCT) [12]. The majority of JMML patients ultimately require HCT for cure [18]. This option was promptly offered to any child with PTEN11, KRAS, or NF1 mutated JMML and to majority of those with NRAS mutations, curing more than 50% of affected children [19].

In addition, genetic and phenotypic heterogeneity has been reported in RASopathy-related syndromes. The occurrence of a pathogenic mutation in the same codon was previously reported, but different clinical diagnoses were established in the individuals studied [2, 20]. Zenker et al. noted that patients diagnosed with Costello syndrome may later develop features of CFC syndrome [3]. Bertola et al. reported the case of a patient with K5E mutation, who was initially diagnosed with the Noonan syndrome, but later the Costello syndrome was confirmed as the final diagnosis [21]. Apart from JMML, the existing phenotypes in our patient, such as multiple malformations, including dysmorphic facial features, cryptorchidism, club feet on both sides, and developmental delay, were inconsistent with those of any of the RASopathy-related syndrome characteristics. The principal feature by which the Noonan syndrome is manifested is congenital heart defects, such as pulmonary valvular stenosis, septal defects or hypertrophic cardiomyopathy, short stature, pectus excavatum, impaired blood clotting, and characteristic facial features [1]. The CFC syndrome is characterized by distinctive facial appearance, sparse and curly scalp hair, ichthyosis, heart malformations, delayed growth, and foot abnormalities [22]. On the other hand, the Costello syndrome is featured by global delayed development, distinctive facial features, heart abnormalities, unusually flexible joints, and loose folds of extra skin, especially on the hands and feet [23]. The phenotypic discrepancy strongly suggests the possibility of another disease or syndrome caused by a second genomic event.

The CMA, which was subsequently conducted, revealed a 10q22.3-q23.2 deletion that was also categorized as pathogenic. In an earlier examination, similar deletions on the long arm of chromosome 10 were reported in six patients, four of which were with mild dysmorphic features and developmental delay [24]. A wide range of cognitive and behavioral phenotypes has been established in multiple family members having this deletion [25]. For example, Van Bon et al. has reviewed 15 cases with
### Table 1 Clinical Feature of Patients With Deletion in 81.6–88.9mb on Chromosome 10

| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---------|---|---|---|---|---|---|---|---|---|----|
| Short stature* | – | – | – | – | – | – | – | – | – | – |
| Developmental delay | + | + | + | + | – | + | + | + | + | + |
| Autism | + | – | + | – | – | – | – | – | – | – |
| Speech delay | + | NA | + | + | – | + | – | – | – | + |
| OFC | P97 | P97 | NA | NA | NA | Macrocephaly | P10 | P2 | P84 | P50 |
| Cardiac defect | NA | NA | PDA | – | – | – | – | AVSD | – | – |
| Reference | Balciuniene et al. [2007] | Balciuniene et al. [2007] | Alliman et al. [2010] | Alliman et al. [2010] | Alliman et al. [2010] | Alliman et al. [2010] | Van Bon et al. [2011] | Van Bon et al. [2011] | Van Bon et al. [2011] | Our case |
| Dysmorphisms and congenital anomalies | Minor features | Ventricular structural abnormalities | Micrognathia | High-arched palate | Hypotonia | High palate | Clubfeet | Hearing loss | Prognathic mandible | Mild hypotonia | Small ears | Wide spaced eyes | Small mouth | Retrognathia | Mild hypotonia | Telecanthus | Low set ears | Hypertelorism | Anterverted nares | Flat nasal bridge | Large mouth | Clubfeet | Low set ears | Hypertelorism | Radioulnar synostosis | Scoliosis | Kyphosis | Pectus excavatum | Café-au-lait spots |
| | | | High upper lip | Wide spaced eyes | Earlobe creases | Prognathic mandible | Rectal bleeding | | | | | | | | | | | | | | | | | Clubfeet | Low set ears | Hypertelorism | Radioulnar synostosis | Scoliosis | Kyphosis | Pectus excavatum | Café-au-lait spots |

AVSD atrial ventricular septal defect, OFC occipito-frontal circumference, PDA patent ductus arteriosus

*Short stature: < 10th centile
10q22.3-q23 deletion or duplication [7] and found that all of the patients showed developmental delay, but their dysmorphisms and congenital anomalies differed considerably. The 10q22.3-q23.2 region is characterized by a complex set of low-copy repeat (LCRs) which can give rise to various genomic changes mediated by nonallelic homologous recombination (NAHR). The longer sequence (approximately 7 Mb) between the LCRs in this region contributes to the lower frequency of recurrent 10q22.3q23 deletion than that of other recurrent deletions or duplication syndromes [25].

Two candidate genes, BMPRIA and GRID1, in the deleted region have been suggested to be related with cardiac defects. Deletion of BMPRIA was found to disrupt the cardiac morphogenesis in mice, resulting in various cardiac defects [26]. A previous meta-analysis of genome-wide association data proposed GRID1 as a candidate gene responsible for the thickness of the left ventricle wall [27]. In our case, nine patients had identical breakpoints (Table 1). Cardiac defects were detected only in two patients, whereas developmental delay (9/10) and dysmorphic facial features (9/10) were manifested in most of the patients. Clinical heterogeneity might also be the reason for the low frequency of 10q22.3q23.2 deletions due to the mild phenotype established in some individuals with this deletion or miscarriages in severe individuals during pregnancy [25].

Molecular testing reveals the underlying genetic variant and thus substantially increases the effectiveness of diagnosis of rare diseases [28]. Furthermore, diagnostic whole-exome sequencing provides opportunities for gaining insights into the relationships between specific multi-locus genomic variations and diseases. Multiple molecular diagnoses by whole-exome sequencing were successfully performed in 4.9% of the patients in a large cohort study. The concurrent pathogenic variants in patients with multiple or ambiguous symptoms partially explained the availability of an intersecant or overlapping phenotype, which contributed to a more convincing molecular diagnosis than that based only on a single outcome [29]. Concurrent pathogenic single-nucleotide and copy number variants are more difficult to detect due to the limitation of the single testing strategy. As CNV detection were progressively optimized by analyzing whole genome exome sequencing or whole sequencing data [30, 31], genetic testing for complicated diseases, especially those with overlapping phenotype, will be more valuable while detecting multiple pathogenic variants.

**Abbreviations**

CFC: Cardio-facio-cutaneous; CMA: Chromosomal microarray analysis; JMML: Juvenile myelomonocytic leukemia; LCRs: Low-copy repeats

**Acknowledgments**

We would like to express our sincere gratitude to our patient and his family for their cooperation.

---

**Funding**

This study was supported by the Shanghai Pujiang Talent Program (No.16PJ1406300 to Tingting Yu) from Shanghai Municipal Science and Technology Commission.

**Availability of data and materials**

The datasets (whole-exome sequencing, chromosomal microarray and Sanger sequencing files) used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

TY and ZY designed and organized the study. YX, LY, and YZ sampled the family members and acquired the clinical data. RY and GL carried out the molecular genetic testing. RY and WJ analyzed and interpreted the genetic testing and clinical data. RY wrote the manuscript, which was then edited by TY and JW. All authors have read and approved the final version of the manuscript submitted by TY.

**Ethics approval and consent to participate**

This study was approved by the Committee on Ethics of the Shanghai Children’s Medical Center (SCCMIRB-K2016013) and was performed in accordance with the Declaration of Helsinki.

**Consent for publication**

Written informed consent was obtained from the patient’s father for publication of this research with patient’s photo, medical record and data.

**Competing interests**

The authors declare that they have no competing interests.

---

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, People’s Republic of China. 2. Institute for Pediatric Translational Medicine, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, People’s Republic of China. 3. Department of Internal Medicine, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, People’s Republic of China. 4. Rare Diseases Outpatient Clinic, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, People’s Republic of China. 5. Department of Pediatric Surgery, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, People’s Republic of China.

Received: 13 June 2018 Accepted: 3 July 2018

Published online: 16 July 2018

**References**

1. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38(3):311–6.

2. Nihori T, Aoki Y, Narumi Y, Neri G, Cavé H, Verloes A, Okamoto N, Hennemann RC, Gillessen-Kaestbach G, Wieczorek D, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006;38(3):294–6.

3. Zenker M, Lehrmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44(2):131–5.

4. Zhao S, Zhang Y, Sha K, Tang Q, Yang X, Yu C, Liu Z, Sun W, Cai L, Xu C, et al. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia. Cell Physiol Biochem. 2014;33(1):7–8.

5. Suda K, Tomizawa K, Mitsuomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010;29(1):49–60.
10. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Delnatte C, Sanlaville D, Mougenot JF, Vermeesch JR, Houdayer C, Blois MC, Lupski JR, Stankiewicz P. Genomic disorders: molecular mechanisms for... 89(10):3534–43.

9. van Bon BW, Balciuniene J, Fruhman G, Nagamani SC, Broome DL, Cameron J, Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81–90.

8. Lüpkes JP, Stankevicius P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet. 2005;1(6):e49.

7. Matsuda K, Shimada A, Yoshida N, Ogawa S, Watanabe A, Yajima S, Iizuka S, Koike K, Yanai F, Kavisuki K, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007;109(12):5477–80.

6. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, Rijntjes-jacobs E, Lopriore E, Steggerda SJ, Kant SG, Walther FJ. Discordance within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet. 2006;78(6):1066–74.

5. Niemeyer CM, Arico M, Basso G, Blond A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kernstrup G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997;89(10):3434–43.

4. Niemeyer CM, Raffeld M, et al. Evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet. 2007;52(6):521–7.

3. Raffeld M, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117(10):2883–6.

2. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science. 1984;223(4637):661–4.

1. Dvorak CC, Loh ML. Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr. 2014;2:35.